This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): intranasal elestat
Description: Epinastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H1-receptor and has affinity for the histamine-H2 receptor. Epinastine also possesses affinity for the a1-adrenergic, a2-adrenergic, and 5-HT2 receptors.
Deal Structure: In February 2006, Inspire entered into a development and license agreement with Boehringer Ingelheim. The agreement granted Inspire certain exclusive rights to develop and market an intranasal dosage form of epinastine, in the United States and Canada, for the treatment or prevention of rhinitis.
Under the terms of the agreement, Inspire will have full responsibility for the intranasal epinastine development program and regulatory filings in the United States and Canada. Upon the receipt of appropriate regulatory approvals for an intranasal epinastine product, Inspire will be responsible for the commercialization of such product in the United States and Canada. Boehringer Ingelheim has retained the rights to develop and commercialize intranasal epinastine outside the United States and Canada, based on any future results of the intranasal epinastine development program.
In addition to funding all development activities under the terms of the agreement, Inspire is required to...See full deal structure in Biomedtracker
Partners: Boehringer Ingelheim GmbH
Epinastine (intranasal) News
Additional information available to subscribers only: